RFL RSI Chart
Last 7 days
-2.8%
Last 30 days
-0.6%
Last 90 days
-4.5%
Trailing 12 Months
-17.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 0 | 0 | 0 | 0 |
2023 | 2.5M | 0 | 3.3M | 0 |
2022 | 682.0K | 562.0K | 201.0K | 1.7M |
2021 | 9.1M | 8.0M | 1.7M | 802.0K |
2020 | 5.2M | 5.1M | 10.4M | 10.3M |
2019 | 4.4M | 4.7M | 4.9M | 5.0M |
2018 | 5.2M | 5.0M | 4.7M | 4.4M |
2017 | 5.6M | 5.6M | 5.6M | 5.6M |
2016 | 0 | 0 | 5.6M | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 04, 2024 | jonas howard s | acquired | - | - | 348,259 | executive chairman |
Apr 04, 2024 | jonas howard s | sold | - | - | -348,259 | executive chairman |
Mar 21, 2024 | conkling william | sold (taxes) | 26,381 | 1.705 | 15,473 | chief executive officer |
Mar 21, 2024 | polinsky david | sold (taxes) | -3,921 | 1.705 | -2,300 | chief financial officer |
Jan 30, 2024 | jonas howard s | acquired | - | - | 348,259 | executive chairman |
Jan 30, 2024 | jonas howard s | sold | - | - | -348,259 | executive chairman |
Jan 05, 2024 | weiss michael j | acquired | 50,055 | 1.81 | 27,655 | - |
Jan 05, 2024 | mccamish mark anthony | acquired | 50,055 | 1.81 | 27,655 | - |
Jan 05, 2024 | greenberg stephen m | acquired | 50,055 | 1.81 | 27,655 | - |
Dec 21, 2023 | polinsky david | sold (taxes) | -15,610 | 1.82 | -8,577 | chief financial officer |
Which funds bought or sold RFL recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 25, 2024 | SIMPLEX TRADING, LLC | reduced | -17.9 | -1,000 | 5,000 | -% |
Apr 24, 2024 | Newbridge Financial Services Group, Inc. | unchanged | - | -165 | 2,580 | -% |
Apr 19, 2024 | Cutler Group LLC / CA | unchanged | - | -1,000 | 9,000 | -% |
Apr 15, 2024 | PFS Partners, LLC | unchanged | - | -160 | 2,494 | -% |
Apr 11, 2024 | OPTIMUM INVESTMENT ADVISORS | unchanged | - | -440 | 6,880 | -% |
Apr 05, 2024 | CWM, LLC | reduced | -97.91 | -1,000 | - | -% |
Mar 22, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | unchanged | - | -140 | 3,660 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 2.03 | -18,529 | 1,051,600 | -% |
Feb 16, 2024 | HARBOUR INVESTMENTS, INC. | unchanged | - | -3.00 | 92.00 | -% |
Feb 16, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | unchanged | - | -2,000 | 54,000 | -% |
Unveiling Rafael Holdings Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Rafael Holdings Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
CSGP | 37.6B | 2.5B | 127.69 | 14.87 | ||||
CBRE | 26.7B | 31.9B | 27.06 | 0.84 | ||||
Z | 10.2B | 1.9B | -64.57 | 5.25 | ||||
MID-CAP | ||||||||
JLL | 8.7B | 20.8B | 38.43 | 0.42 | ||||
JOE | 3.4B | 404.1M | 42.07 | 8.46 | ||||
DBRG | 2.7B | 821.4M | 14.47 | 3.26 | ||||
CWK | 2.2B | 9.5B | -62.48 | 0.23 | ||||
SMALL-CAP | ||||||||
EXPI | 1.6B | 4.3B | -174.44 | 0.37 | ||||
ARL | 222.4M | 50.5M | 56.05 | 4.4 | ||||
AXR | 109.5M | 44.5M | 49.12 | 2.46 | ||||
CHCI | 68.9M | 44.7M | 8.86 | 1.54 | ||||
ASPS | 52.6M | 145.1M | -1 | 0.36 |
Rafael Holdings Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | 22.5% | 6,008,000 | 4,902,500 | 3,797,000 | 2,691,500 | 1,586,000 | 81,000 | - | - | 120,000 | 442,000 | 120,000 | 120,000 | 1,053,000 | 6,745,000 | 1,224,000 | 1,236,000 | 1,210,000 | 1,416,000 | 1,377,000 | 1,017,000 | 1,107,000 |
S&GA Expenses | 25.5% | 2,561,000 | 2,040,000 | 1,395,000 | 2,085,000 | 3,109,000 | 3,048,000 | 3,336,000 | -1,680,000 | 12,274,000 | 8,659,000 | 3,006,000 | 2,767,000 | 2,592,000 | 2,775,000 | 2,081,000 | 2,221,000 | 2,041,000 | 3,593,000 | 2,059,000 | 1,716,000 | 1,453,000 |
R&D Expenses | 25.2% | 612,000 | 489,000 | 1,266,000 | 2,225,000 | 2,081,000 | 1,841,000 | 1,413,000 | 3,335,000 | 2,153,000 | 1,562,000 | 1,262,000 | 1,568,000 | 515,000 | 1,064,000 | 634,000 | 448,000 | 245,000 | 78,000 | 300,000 | 276,000 | 373,000 |
EBITDA Margin | 133.8% | 0.73 | -2.15 | -2.66 | -7.32 | -10.08 | -696 | -261 | -212 | -187 | -13.46 | -1.58 | -1.31 | -0.49 | -0.49 | -1.17 | -0.97 | -0.75 | -0.55 | -0.34 | -0.19 | -0.37 |
Interest Expenses | - | - | - | - | - | - | -13,000 | 1,000 | - | 13,000 | 7,000 | 3,000 | -1,000 | - | -1,000 | - | 33,000 | -64,000 | -178,000 | -221,000 | 767,000 | 101,000 |
Income Taxes | -100.0% | - | 6,000 | 4,000 | 5,000 | 5,000 | - | 2,000 | 4,000 | - | 5,000 | 4,000 | 4,000 | 5,000 | 5,000 | 8,000 | 12,000 | 4,000 | 2,000 | -7,000 | 17,000 | -31,000 |
Earnings Before Taxes | 272.7% | 6,110,000 | -3,538,000 | 1,463,000 | -3,247,000 | -5,202,000 | -4,645,000 | -4,981,000 | -2,053,000 | -128,293,000 | -10,833,000 | -2,742,000 | -8,329,000 | -1,522,000 | -1,664,000 | -2,288,000 | -1,316,000 | -1,648,000 | -2,409,000 | -1,154,000 | -684,000 | -696,000 |
EBT Margin | 132.1% | 0.70 | -2.18 | -2.69 | -7.35 | -10.13 | -696 | -260 | -211 | -187 | -13.50 | -1.77 | -1.51 | -0.66 | -0.66 | -1.51 | -1.25 | -1.17 | -1.01 | -0.83 | -0.77 | -0.79 |
Net Income | 266.2% | 6,047,000 | -3,638,000 | 7,142,116,500 | -3,250,000 | 1,592,000 | 4,717,958,500 | -5,548,000 | -2,057,000 | -128,868,000 | -10,743,000 | -2,650,000 | -8,237,000 | -1,431,000 | -5,743,000 | -2,159,000 | -1,253,000 | -1,598,000 | -2,186,000 | -1,005,000 | -1,021,000 | -481,000 |
Net Income Margin | 0.3% | 771 | 768 | 768 | 513 | 757 | 6,261 | -261 | -211 | -187 | -13.29 | -2.25 | -1.92 | -1.03 | -1.03 | -1.41 | -1.15 | -1.16 | -0.95 | -0.67 | -0.60 | -0.50 |
Free Cashflow | -18.6% | -2,529,000 | -2,133,000 | -1,449,000 | -5,545,000 | -2,581,000 | -1,903,000 | -10,365,000 | -7,310,000 | -6,503,000 | -6,950,000 | -3,125,000 | -2,934,000 | -2,798,000 | -1,734,000 | -1,110,000 | -1,099,000 | -1,257,000 | -629,000 | -1,945,000 | -207,000 | -750,000 |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 11.1% | 106 | 96.00 | 99.00 | 96.00 | 99.00 | 103 | 118 | 113 | 123 | 130 | 154 | 146 | 146 | 135 | 136 | 137 | 139 | 140 | 142 | 143 | 144 |
Current Assets | -3.1% | 75.00 | 77.00 | 83.00 | 85.00 | 90.00 | 95.00 | 108 | 63.00 | 72.00 | 79.00 | 15.00 | 6.00 | 7.00 | 8.00 | 10.00 | 9.00 | 10.00 | 12.00 | 13.00 | 15.00 | 16.00 |
Cash Equivalents | -45.9% | 7.00 | 13.00 | 21.00 | 15.00 | 10.00 | 23.00 | 27.00 | 29.00 | 70.00 | 72.00 | 13.00 | 5.00 | 6.00 | 7.00 | 6.00 | 8.00 | 10.00 | 11.00 | 12.00 | 13.00 | 15.00 |
Net PPE | 23.5% | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 42.00 | 43.00 | 43.00 | 2.00 | 44.00 | 44.00 | 44.00 | 44.00 | 48.00 | 48.00 | 49.00 | 49.00 | 49.00 | 49.00 |
Goodwill | - | 4.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Liabilities | 293.4% | 4.00 | 1.00 | 2.00 | 1.00 | 2.00 | 3.00 | 21.00 | 18.00 | 23.00 | 17.00 | 17.00 | 5.00 | 11.00 | 5.00 | 6.00 | 2.00 | 1.00 | 1.00 | 17.00 | 17.00 | 16.00 |
Current Liabilities | 249.4% | 3.00 | 1.00 | 2.00 | 1.00 | 2.00 | 3.00 | 21.00 | 18.00 | 23.00 | 17.00 | 17.00 | 5.00 | 11.00 | 5.00 | 6.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Shareholder's Equity | 11.0% | 105 | 95.00 | 100 | 99.00 | 97.00 | 100 | 97.00 | 95.00 | 100 | 113 | 137 | 141 | 135 | 129 | 131 | 136 | 138 | 139 | 125 | 127 | 128 |
Retained Earnings | 3.5% | -164 | -170 | -167 | -168 | -167 | -163 | -165 | -160 | -155 | -152 | -40.80 | -28.42 | -25.87 | -17.70 | -16.25 | -10.85 | -8.69 | -7.44 | -5.84 | -3.65 | -2.65 |
Additional Paid-In Capital | 0.3% | 266 | 265 | 264 | 264 | 263 | 263 | 262 | 255 | 254 | 265 | 159 | 151 | 143 | 129 | 129 | 129 | 129 | 129 | 113 | 117 | 117 |
Shares Outstanding | 0.0% | 24.00 | 24.00 | 23.00 | 23.00 | 23.00 | 23.00 | 20.00 | 20.00 | 20.00 | 19.00 | 17.00 | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | 13.00 | 13.00 | 13.00 |
Minority Interest | 27.3% | -2.68 | -3.69 | -3.66 | -3.64 | -3.57 | -3.41 | -3.31 | -3.24 | -3.22 | -2.97 | 14.00 | 14.00 | 15.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 9.00 | 9.00 |
Float | - | - | - | - | - | 70.00 | - | - | - | 70.00 | - | - | - | 330 | - | - | - | 184 | - | - | - | 96.00 |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -18.6% | -2,529 | -2,133 | -1,448 | -1,314 | -5,544 | -2,580 | -1,902 | -10,366 | -7,337 | -6,474 | -6,981 | -3,093 | -2,874 | -2,653 | -1,691 | -1,075 | -964 | -936 | -594 | -1,639 | -175 |
Share Based Compensation | 10.2% | 715 | 649 | 540 | 591 | -123 | 1,180 | 1,172 | 1,008 | -10,948 | 7,851 | 5,610 | 304 | 505 | 214 | 242 | 135 | 109 | 94.00 | - | - | - |
Cashflow From Investing | 58.9% | -2,791 | -6,786 | 7,407 | 7,387 | -7,557 | 13,974 | -6,377 | -30,482 | -33.00 | -26,904 | 531 | -282 | -12,058 | 3,638 | -543 | -35.00 | -135 | -321 | -35.00 | -306 | -25,738 |
Cashflow From Financing | -215.5% | -932 | 807 | -35.00 | -26.00 | -151 | -15,006 | 5,997 | -1.00 | -41.00 | 97,909 | 14,528 | 1,961 | 13,766 | 43.00 | - | 20.00 | - | - | 35.00 | 27.00 | 30,709 |
Buy Backs | 12.7% | 89.00 | 79.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jan. 31, 2024 | Jan. 31, 2023 | Jan. 31, 2024 | Jan. 31, 2023 | |
REVENUE | ||||
Total revenue | $ 68 | $ 70 | $ 136 | $ 140 |
COSTS AND EXPENSES | ||||
General and administrative | 2,561 | 2,085 | 4,601 | 5,194 |
Research and development | 612 | 2,225 | 1,101 | 4,306 |
Depreciation and amortization | 38 | 19 | 55 | 41 |
Loss from operations | (3,143) | (4,259) | (5,621) | (9,401) |
Interest income | 693 | 562 | 1,275 | 770 |
Impairment of investments - Other Pharmaceuticals | (67) | (223) | ||
Loss on initial investment in Day Three upon acquisition | (1,633) | (1,633) | ||
Realized gain on available-for-sale securities | 399 | 139 | 576 | 154 |
Realized loss on investment in equity securities | (46) | |||
Realized gain on investments - Cyclo Therapeutics Inc. | 424 | |||
Unrealized gain on investments - Cyclo Therapeutics Inc. | 9,718 | 7,594 | ||
Unrealized gain (loss) on investments - Hedge Funds | 51 | 378 | (115) | 251 |
Other Income | 25 | 118 | ||
Income (loss) from continuing operations before income taxes | 6,110 | (3,247) | 2,572 | (8,449) |
Provision for income taxes | (5) | (6) | (10) | |
Equity in loss of Day Three | (206) | (422) | ||
Consolidated net income (loss) from continuing operations | 5,904 | (3,252) | 2,144 | (8,459) |
Discontinued Operations (Note 3) | ||||
Loss from discontinued operations related to 520 Property | (157) | (241) | ||
Gain on disposal of 520 Property | 6,784 | |||
Income (loss) from discontinued operations | (157) | 6,543 | ||
Consolidated net income (loss) | 5,904 | (3,409) | 2,144 | (1,916) |
Net loss attributable to noncontrolling interests | (143) | (159) | (265) | (258) |
Net income (loss) attributable to Rafael Holdings, Inc. | 6,047 | (3,250) | 2,409 | (1,658) |
Unrealized gain on available-for-sale securities | 58 | 268 | 265 | 371 |
Foreign currency translation adjustment | 46 | (16) | (30) | (26) |
Comprehensive income (loss) | 6,008 | (3,157) | 2,379 | (1,571) |
Comprehensive loss attributable to noncontrolling interests | (145) | (156) | (264) | (255) |
Comprehensive income (loss) attributable to Rafael Holdings, Inc. | $ 6,153 | $ (3,001) | $ 2,643 | $ (1,316) |
Basic: | ||||
Continuing operations (in Dollars per share) | $ 0.26 | $ (0.13) | $ 0.1 | $ (0.36) |
Discontinued operations (in Dollars per share) | (0.01) | 0.28 | ||
Total basic income (loss) per share (in Dollars per share) | 0.26 | (0.14) | 0.1 | (0.08) |
Diluted: | ||||
Continuing operations (in Dollars per share) | 0.25 | (0.13) | 0.1 | (0.36) |
Discontinued operations (in Dollars per share) | (0.01) | 0.28 | ||
Total diluted income (loss) per share (in Dollars per share) | $ 0.25 | $ (0.14) | $ 0.1 | $ (0.08) |
Weighted average number of shares used in calculation of income (loss) per share | ||||
Basic (in Shares) | 23,642,421 | 23,155,018 | 23,643,660 | 23,085,612 |
Diluted (in Shares) | 24,402,069 | 23,155,018 | 24,403,308 | 23,085,612 |
Rental – Third Party | ||||
REVENUE | ||||
Total revenue | $ 41 | $ 43 | $ 82 | $ 86 |
Rental – Related Party | ||||
REVENUE | ||||
Total revenue | $ 27 | $ 27 | $ 54 | $ 54 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Jan. 31, 2024 | Jul. 31, 2023 |
---|---|---|
CURRENT ASSETS | ||
Cash and cash equivalents | $ 7,136 | $ 21,498 |
Available-for-sale securities | 64,587 | 57,714 |
Interest receivable | 560 | 387 |
Accounts receivable, net of allowance for doubtful accounts of $245 at January 31, 2024 and July 31, 2023 | 379 | 213 |
Prepaid expenses and other current assets | 487 | 914 |
Investment in equity securities | 294 | |
Total current assets | 75,073 | 82,941 |
Property and equipment, net | 2,064 | 1,695 |
Goodwill | 3,571 | |
Intangible assets | 1,888 | |
In-process research and development | 1,575 | 1,575 |
Other assets | 42 | 9 |
TOTAL ASSETS | 106,149 | 98,829 |
CURRENT LIABILITIES | ||
Accounts payable | 509 | 333 |
Accrued expenses | 845 | 763 |
Other current liabilities | 140 | 1,023 |
Installment note payable | 1,700 | |
Total current liabilities | 3,263 | 2,145 |
Deferred income tax liabilities, net | 545 | |
Other liabilities | 87 | 55 |
TOTAL LIABILITIES | 3,895 | 2,200 |
COMMITMENTS AND CONTINGENCIES | ||
EQUITY | ||
Additional paid-in capital | 266,159 | 264,010 |
Accumulated deficit | (164,924) | (167,333) |
Treasury stock, at cost; 101,487 and 0 Class B shares as of January 31, 2024 and July 31, 2023, respectively | (168) | |
Accumulated other comprehensive loss related to unrealized loss on available-for-sale securities | (88) | (353) |
Accumulated other comprehensive income related to foreign currency translation adjustment | 3,714 | 3,725 |
Total equity | 104,939 | 100,293 |
Noncontrolling interests | (2,685) | (3,664) |
TOTAL EQUITY ATTRIBUTABLE TO RAFAEL HOLDINGS, INC. | 102,254 | 96,629 |
TOTAL LIABILITIES AND EQUITY | 106,149 | 98,829 |
Class A Common Stock | ||
EQUITY | ||
Common stock value | 8 | 8 |
Class B Common Stock | ||
EQUITY | ||
Common stock value | 238 | 236 |
Other Pharmaceuticals | ||
CURRENT ASSETS | ||
Investments | 65 | |
Hedge Funds | ||
CURRENT ASSETS | ||
Investments | 2,369 | 4,984 |
Day Three | ||
CURRENT ASSETS | ||
Investments | 2,797 | |
Cyclo Therapeutics Inc. | ||
CURRENT ASSETS | ||
Investments | 19,567 | 4,763 |
Related Party | ||
CURRENT ASSETS | ||
Convertible note receivable, related party | 1,924 | 1,921 |
CURRENT LIABILITIES | ||
Due to related parties | $ 69 | $ 26 |